<DOC>
	<DOCNO>NCT02367248</DOCNO>
	<brief_summary>The main purpose study determine whether deferoxamine xingnaojing injection effective safe treatment intracerebral hemorrhage .</brief_summary>
	<brief_title>Deferoxamine Xingnaojing Injection Treatment Intracerebral Hemorrhage</brief_title>
	<detailed_description>Research show 1/3 patient acute cerebral hemorrhage first 24 hour expand hematoma . The treatment acute cerebral hemorrhage two main target : prevention hematoma enlargement primary brain damage ; Reduce hematoma secondary brain damage cause blood toxicity degradation product . At present , curative effect drug treatment acute cerebral hemorrhage remain limited , use drug therapy treat hematoma cause blood toxicity degradation product secondary brain damage , one main current international research direction hotspot . Recent study find iron overload cell acute cerebral hemorrhage stave week edema secondary lesion play important role . Acute cerebral hemorrhage animal model research small sample clinical study show iron chelator deferoxamine good curative effect security . Currently ongoing international HI-DEF test plan assess efficacy safety high-dose deferoxamine treatment within 24 h patient acute cerebral hemorrhage . Basic research show Xingnaojing injection inhibit inflammatory reaction , scavenge free radical , relieve acute cerebral hemorrhage hematoma surround edema variety brain protection mechanism . The current study build result assess potential utility deferoxamine Xingnaojing injection therapeutic intervention ICH . This prospective , multi-center , double-blind , randomize , placebo-armed clinical study test safety effectiveness deferoxamine Xingnaojing injection treatment intracerebral hemorrhage . The investigator randomize 180 subject ICH equally ( 1:1:1 ) either DFO 40mg/kg/day ( maximum daily dose 6000 mg/day ) , Xingnaojing injection , saline placebo , give continuous IV infusion 5 consecutive day . Treatment initiate within 12 hour ICH symptom onset . The main objective : 1 . Examining effect DFO Xingnaojing injection peri-hematoma edema ( PHE ) volume progression baseline post-treatment CT/MRI scan residual cavity volume 90 day . 2 . Obtaining data National Institute Health Stroke Scale ( NIHSS ) explore effect treatment neurological function . 3 . Examining effect DFO Xingnaojing injection biomarkers acute cerebral hemorrhage ferritin , interleukin - 6 , matrix metalloproteinase 9 , tumor necrosis factor alpha . 4 . Study traditional Chinese medicine ( TCM ) curative effect evaluation role different treatment method secondary damage ICH . Secondary exploratory objective include : 1 . Exploring whether effect DFO outcome dependent initial ICH volume , adjust prognostic variable , determine specific limit ICH volume specify exclusion/inclusion criterion future study . 2 . Exploring difference early ( ≤12h ) late ( &gt; 12-24h ) OTT windows DFO treatment effect functional outcome . Exploratory study show iron chelator deferoxamine effective safe treatment acute cerebral hemorrhage . We choose within 12 hour treatment time window , different within 24 hour current international ongoing HI-DEF test . In theory , early , well curative effect . So experiment likely get well curative effect . Xingnaojing injection widely use clinical china , lack rigorous randomize control trial prove brain protection effect currently . Successful completion study provide crucial , reliable experimental evidence new treatment acute cerebral hemorrhage . ICH one main cause disability death . A successful study demonstrate efficacy DFO xingnaojing injection would considerable public health significance .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Deferoxamine</mesh_term>
	<criteria>1 . Age ≥ 18 ≤ 80 year 2 . The diagnosis ICH confirm brain CT scan 3 . NIHSS score ≥ 6 GCS &gt; 6 upon presentation 4 . The first dose study drug administer within 12h ICH symptom onset 5 . Functional independence prior ICH , define preICH mRS ≤ 1 6 . Signed date informed consent obtain . 1 . Known hypersensitivity deferoxamine xingnaojing injection 2 . Known severe iron deficiency anemia ( define hemoglobin concentration &lt; 7g/dL require blood transfusion ) 3 . Abnormal renal function , define serum creatinine &gt; 2 mg/dL 4 . Planned surgical evacuation ICH prior administration study drug 5 . Suspected secondary ICH relate tumour , rupture aneurysm arteriovenous malformation , hemorrhagic transformation ischemic infarct , venous sinus thrombosis 6 . Infratentorial hemorrhage 7 . Irreversibly impaired brainstem function ( bilateral fix dilate pupil extensor motor posturing ) 8 . Complete unconsciousness , define score 3 item 1a NIHSS ( Responds reflex motor autonomic effect totally unresponsive , flaccid ) 9 . Preexisting disability , define preICH mRS ≥ 2 10 . Coagulopathy define elevate aPTT INR &gt; 1.3 upon presentation ; concurrent use direct thrombin inhibitor ( dabigatran ) , direct factor Xa inhibitor ( rivaroxaban ) , lowmolecularweight heparin 11 . Taking iron supplement contain ≥ 325 mg ferrous iron 12 . Patients heart failure take &gt; 500 mg vitamin C daily 13 . Known severe hearing loss 14 . Known pregnancy , positive pregnancy test , breastfeed 15 . Patients know suspected able comply study protocol due alcoholism , drug dependency , noncompliance , live another state cause 16 . Life expectancy le 90 day due comorbid condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Brain hemorrhage</keyword>
	<keyword>Cerebral Hemorrhage</keyword>
	<keyword>Deferoxamine</keyword>
	<keyword>Xingnaojing injection</keyword>
	<keyword>Hematoma edema</keyword>
</DOC>